Principal Investigators

    A/Pr Trent Woodruff


    University of Queensland

    Contact information of lead PI



    Title of project or programme

    Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease

    Source of funding information

    National Health and Medical Research Council

    Total sum awarded (Euro)

    € 332,144

    Start date of award


    Total duration of award in years



    Research Abstract

    Parkinson’s disease is the second most common neurological disease in Australia, yet there is no treatment to slow disease progression. Our study is investigating inflammation within the brain as a major contributing factor in Parkinson’s disease. We will examine this inflammatory pathway in human patients suffering from Parkinson’s, and will test a novel anti-inflammatory drug in animal models of Parkinson’s disease, in order to identify a novel treatment to reduce disease pathology.

    Further information available at:

Types: Investments < €500k
Member States: Australia
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF